LOUIS VIGNATI, M.D.
Osteopathic Medicine at Olde Mill Circle West Dr, Indianapolis, IN
License number
Indiana 01038821B
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
8515 Olde Mill Circle West Dr WEST, Indianapolis, IN 46260
Phone
(317) 254-1686
Personal information
See more information about LOUIS VIGNATI at radaris.comName
Address
Phone
5617 N Meridian St, Indianapolis, IN 46208
5617 Meridian St, Indianapolis, IN 46208
8515 Olde Mill Circle West Dr, Indianapolis, IN 46260
Professional information
Vice President Medical At Marcadia Biotech
Location:
Indianapolis, Indiana Area
Industry:
Biotechnology
Work:
Marcadia Biotech
Sep 2006 - Apr 2011
-
Vice President Medical
Eli Lilly
1990 - 2006
-
Distinguised Medical Fellow
Education:
Thomas Jefferson University 1966 - 1970
M.D. American University 1964 - 1966
M.S., Organic Chemistry University of Pennsylvania 1960 - 1964
BA, Chemistry
M.D. American University 1964 - 1966
M.S., Organic Chemistry University of Pennsylvania 1960 - 1964
BA, Chemistry
Dr. Louis Vignati, Indianapolis IN - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism, Endocrinology & Metabolism
Address:
8515 Olde Mill Circle West Dr, Indianapolis 46260
(317) 254-1686 (Phone)
(317) 254-1686 (Phone)
Certifications:
Diabetes, Metabolism & Endocrinology, 1983, Internal Medicine, 1975
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Thomas Jefferson University
Graduated: 1970
Ctr Hosp Vt
Peter Bent Brigham Hosp
Thomas Jefferson University
Graduated: 1970
Ctr Hosp Vt
Peter Bent Brigham Hosp
Method For Treating Non-Insulin Dependent Diabetes Using Thiazolidinediones With Glucagonlike Peptide-1 And Agonists Thereof
US Patent:
RE40876, Aug 18, 2009
Filed:
Jun 6, 2000
Appl. No.:
11/650410
Inventors:
Lawrence Edward Stramm - Indianapolis IN, US
Louis Vignati - Indianapolis IN, US
William Terry Johnson - Cape Coral FL, US
Louis Vignati - Indianapolis IN, US
William Terry Johnson - Cape Coral FL, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 38/00, A61K 31/50
US Classification:
514 2, 530308, 530300, 51425201
Abstract:
Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while minimizing side effects, such as heart hypertrophy and elevated fed-state plasma glucose, which are associated with both TZD and GLP-1 monotherapies. Thus, the co-administration of TZD and GLP-1 helps regulate glucose homeostasis in Type II diabetic patients.
Synergistic Use Of Thiazolidinediones With Glucagon-Like Peptide-1 And Agonists Thereof To Treat Metabolic Instability Associated With Non-Insulin Dependent Diabetes
US Patent:
7223728, May 29, 2007
Filed:
Oct 6, 2003
Appl. No.:
10/679746
Inventors:
Lawrence Edward Stramm - Indianapolis IN, US
William Terry Johnson - Indianapolis IN, US
Louis Vignati - Indianapolis IN, US
William Terry Johnson - Indianapolis IN, US
Louis Vignati - Indianapolis IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A38K 38/00, A61K 31/50
US Classification:
514 2, 51425201, 530300, 530308
Abstract:
Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used, in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while minimizing side effects, such as heart hypertrophy and elevated fed-state plasma glucose, which are associate with both TZD and GLP-1 monotherapies. Thus, the co-administration of TZD and GLP-1 helps regulate glucose homeostasis in Type II diabetic patients.
Combination Methods For Preserving Visual Acuity
US Patent:
2008023, Sep 25, 2008
Filed:
Sep 18, 2006
Appl. No.:
12/064883
Inventors:
Matthew John Sheetz - Indianapolis IN, US
Louis Vignati - Indianapolis IN, US
Xin Zhi - Indianapolis IN, US
Louis Vignati - Indianapolis IN, US
Xin Zhi - Indianapolis IN, US
International Classification:
A61K 31/407, A61P 3/10, A61P 27/02
US Classification:
514410
Abstract:
The present invention relates to a method for preserving the vision of a patient suffering from diabetic retinopathy which comprises administering to said patient an effective amount of ruboxistaurin or a pharmaceutical salt thereof wherein said administration is in conjunction with focal or grid laser photocoagulation therapy.
Methods For Treating Metabolic Disorders And Obesity With Gip And Glp-1 Receptor-Active Glucagon-Based Peptides
US Patent:
2014001, Jan 16, 2014
Filed:
Dec 22, 2011
Appl. No.:
13/996937
Inventors:
Louis Vignati - Indianapolis IN, US
Richard D. Dimarchi - Carmel IN, US
Richard D. Dimarchi - Carmel IN, US
Assignee:
MARCADIA BIOTECH, INC. - Nutley NJ
International Classification:
A61K 38/26, A61K 45/06
US Classification:
514 53, 514 68, 514 72
Abstract:
Methods are provided for administering an extended half-life GLP-1/GIP coagonist peptide to a patient in need thereof for reducing weight gain, inducing weight loss, treating hyperglycemia, reducing blood glucose levels, or normalizing blood glucose levels in said patient.
Therapeutic Treatment For Skin Disorders
US Patent:
6093740, Jul 25, 2000
Filed:
Apr 9, 1998
Appl. No.:
9/057541
Inventors:
Michael Robert Jirousek - Indianapolis IN
Lawrence E. Stramm - Indianapolis IN
Louis Vignati - Indianapolis IN
Douglas Kirk Ways - Indianapolis IN
Lawrence E. Stramm - Indianapolis IN
Louis Vignati - Indianapolis IN
Douglas Kirk Ways - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 3140, A61K 31405, C07D20904, C07D40314
US Classification:
514414
Abstract:
A method for reducing or inhibiting vascular permeability especially the increased vascular permeability associated with VPF/VEGF, and dermal edema exhibited with bullous phemigoid, erythema multiforme, dermatitis herpetiformis, contact dermatitis/delayed hypersensitivity is disclosed, particularly using the. beta. -isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis -(3,3'-indolyl)]-1(H)-pyrrole-2,5-dione and its pharmaceutically acceptable salts.
Therapeutic Treatment For Vegf Related Ocular Diseases
US Patent:
6114320, Sep 5, 2000
Filed:
Apr 30, 1997
Appl. No.:
8/841739
Inventors:
Lloyd P. Aiello - Belmont MA
Michael R. Jirousek - Indianapolis IN
George L. King - Dover MA
Louis Vignati - Indianapolis IN
Douglas Kirk Ways - Indianapolis IN
Michael R. Jirousek - Indianapolis IN
George L. King - Dover MA
Louis Vignati - Indianapolis IN
Douglas Kirk Ways - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
Joslin Diabetes Center - Boston MA
Joslin Diabetes Center - Boston MA
International Classification:
A61K 3133, A61K 31555
US Classification:
514185
Abstract:
A method for inhibiting VEGF stimulated endothelial cell growth, such as associated with macular degeneration, and VEGF stimulated capillary permeability, such as associated with macular edema are disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis -(3,3'-indoly 1)]-1(H)-pyrrole-2,5-dionehydrochloridesalt.
Therapeutic Treatment For Vegf Related Diseases
US Patent:
6284751, Sep 4, 2001
Filed:
Jun 18, 1999
Appl. No.:
9/335887
Inventors:
Lloyd P. Aiello - Belmont MA
Michael R. Jirousek - Indianapolis IN
George L. King - Dover MA
Louis Vignati - Indianapolis IN
Douglas Kirk Ways - Indianapolis IN
Michael R. Jirousek - Indianapolis IN
George L. King - Dover MA
Louis Vignati - Indianapolis IN
Douglas Kirk Ways - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 3133, A61K 31555, A61K 3140
US Classification:
514183
Abstract:
A method for inhibiting VEGF stimulated endothelial cell growth, such as associated with neoplasia, and VEGF stimulated capillary permeability, such as associated with pulmonary edema are disclosed, particularly using the. beta. -isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis -(3,3'-indolyl)]-1(H)-pyrrole-2,5-dionehydrochloridesalt.